Which has preferable valuation & earnings, ALGN or DVA?

DaVita has higher revenue and earnings than Align Technology. DaVita is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Align Technology $4.03B 3.01 $410.35M $5.96 28.48 DaVita $13.64B 0.90 $746.80M $10.78 17.65

Is ALGN or DVA more profitable?

Align Technology has a net margin of 10.50% compared to DaVita's net margin of 5.65%. Align Technology's return on equity of 15.82% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets Align Technology 10.50% 15.82% 10.17% DaVita 5.65% -270.37% 4.87%

Does the media favor ALGN or DVA?

In the previous week, Align Technology had 3 more articles in the media than DaVita. MarketBeat recorded 7 mentions for Align Technology and 4 mentions for DaVita. DaVita's average media sentiment score of 0.81 beat Align Technology's score of 0.51 indicating that DaVita is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Align Technology 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive DaVita 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, DXCM or DVA?

DexCom has higher earnings, but lower revenue than DaVita. DaVita is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 6.20 $836.30M $2.34 32.00 DaVita $13.64B 0.90 $746.80M $10.78 17.65

Is DXCM or DVA more profitable?

DexCom has a net margin of 19.31% compared to DaVita's net margin of 5.65%. DexCom's return on equity of 33.33% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 19.31% 33.33% 13.19% DaVita 5.65% -270.37% 4.87%

Does the media favor DXCM or DVA?

In the previous week, DexCom had 23 more articles in the media than DaVita. MarketBeat recorded 27 mentions for DexCom and 4 mentions for DaVita. DexCom's average media sentiment score of 1.24 beat DaVita's score of 0.81 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 22 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive DaVita 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, HQY or DVA?

DaVita has higher revenue and earnings than HealthEquity. DaVita is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HealthEquity $1.31B 5.77 $215.20M $2.67 33.95 DaVita $13.64B 0.90 $746.80M $10.78 17.65

Is HQY or DVA more profitable?

HealthEquity has a net margin of 17.25% compared to DaVita's net margin of 5.65%. HealthEquity's return on equity of 14.75% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets HealthEquity 17.25% 14.75% 9.22% DaVita 5.65% -270.37% 4.87%

Does the media favor HQY or DVA?

In the previous week, HealthEquity had 13 more articles in the media than DaVita. MarketBeat recorded 17 mentions for HealthEquity and 4 mentions for DaVita. DaVita's average media sentiment score of 0.81 beat HealthEquity's score of 0.79 indicating that DaVita is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthEquity 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DaVita 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, DVA or MMSI?

DaVita has higher revenue and earnings than Merit Medical Systems. DaVita is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DaVita $13.64B 0.90 $746.80M $10.78 17.65 Merit Medical Systems $1.52B 2.44 $128.49M $2.31 26.86

Does the media refer more to DVA or MMSI?

In the previous week, Merit Medical Systems had 7 more articles in the media than DaVita. MarketBeat recorded 11 mentions for Merit Medical Systems and 4 mentions for DaVita. DaVita's average media sentiment score of 0.81 beat Merit Medical Systems' score of 0.80 indicating that DaVita is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Merit Medical Systems 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, DVA or CAH?

Cardinal Health has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DaVita $13.64B 0.90 $746.80M $10.78 17.65 Cardinal Health $222.58B 0.21 $1.56B $6.54 29.87

Is DVA or CAH more profitable?

DaVita has a net margin of 5.65% compared to Cardinal Health's net margin of 0.62%. Cardinal Health's return on equity of -92.61% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets DaVita 5.65% -270.37% 4.87% Cardinal Health 0.62% -92.61% 4.46%

Does the media refer more to DVA or CAH?

In the previous week, DaVita and DaVita both had 4 articles in the media. Cardinal Health's average media sentiment score of 0.97 beat DaVita's score of 0.81 indicating that Cardinal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardinal Health 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DaVita (DVA) Competitors

$190.28 -4.08 (-2.10%)

Closing price 03:59 PM Eastern

Extended Trading

$190.95 +0.67 (+0.35%)

As of 05:16 PM Eastern

Compare

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

Should you buy DaVita stock or one of its competitors? MarketBeat compares DaVita with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DaVita include Align Technology (ALGN), DexCom (DXCM), HealthEquity (HQY), Merit Medical Systems (MMSI), and Cardinal Health (CAH). These companies are all part of the "medical" sector.

How does DaVita compare to Align Technology?

Align Technology (NASDAQ:ALGN) and DaVita (NYSE:DVA) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

In the previous week, Align Technology had 3 more articles in the media than DaVita. MarketBeat recorded 7 mentions for Align Technology and 4 mentions for DaVita. DaVita's average media sentiment score of 0.81 beat Align Technology's score of 0.51 indicating that DaVita is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Align Technology	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
DaVita	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Align Technology has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, DaVita has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

DaVita has higher revenue and earnings than Align Technology. DaVita is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Align Technology	$4.03B	3.01	$410.35M	$5.96	28.48
DaVita	$13.64B	0.90	$746.80M	$10.78	17.65

88.4% of Align Technology shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 0.8% of Align Technology shares are held by insiders. Comparatively, 1.5% of DaVita shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Align Technology has a net margin of 10.50% compared to DaVita's net margin of 5.65%. Align Technology's return on equity of 15.82% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Align Technology	10.50%	15.82%	10.17%
DaVita	5.65%	-270.37%	4.87%

Align Technology currently has a consensus target price of $205.85, indicating a potential upside of 21.25%. DaVita has a consensus target price of $199.17, indicating a potential upside of 4.67%. Given Align Technology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Align Technology is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Align Technology	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.57
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38

Summary

Align Technology beats DaVita on 10 of the 17 factors compared between the two stocks.

How does DaVita compare to DexCom?

DexCom (NASDAQ:DXCM) and DaVita (NYSE:DVA) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

DexCom presently has a consensus target price of $82.42, indicating a potential upside of 10.08%. DaVita has a consensus target price of $199.17, indicating a potential upside of 4.67%. Given DexCom's stronger consensus rating and higher probable upside, analysts plainly believe DexCom is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38

DexCom has a net margin of 19.31% compared to DaVita's net margin of 5.65%. DexCom's return on equity of 33.33% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
DaVita	5.65%	-270.37%	4.87%

In the previous week, DexCom had 23 more articles in the media than DaVita. MarketBeat recorded 27 mentions for DexCom and 4 mentions for DaVita. DexCom's average media sentiment score of 1.24 beat DaVita's score of 0.81 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	22 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
DaVita	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom has higher earnings, but lower revenue than DaVita. DaVita is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	6.20	$836.30M	$2.34	32.00
DaVita	$13.64B	0.90	$746.80M	$10.78	17.65

DexCom has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, DaVita has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

97.8% of DexCom shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 1.5% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

DexCom beats DaVita on 14 of the 17 factors compared between the two stocks.

How does DaVita compare to HealthEquity?

HealthEquity (NASDAQ:HQY) and DaVita (NYSE:DVA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

HealthEquity has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, DaVita has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

DaVita has higher revenue and earnings than HealthEquity. DaVita is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthEquity	$1.31B	5.77	$215.20M	$2.67	33.95
DaVita	$13.64B	0.90	$746.80M	$10.78	17.65

HealthEquity presently has a consensus price target of $111.53, suggesting a potential upside of 23.05%. DaVita has a consensus price target of $199.17, suggesting a potential upside of 4.67%. Given HealthEquity's stronger consensus rating and higher possible upside, analysts clearly believe HealthEquity is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthEquity	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38

HealthEquity has a net margin of 17.25% compared to DaVita's net margin of 5.65%. HealthEquity's return on equity of 14.75% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthEquity	17.25%	14.75%	9.22%
DaVita	5.65%	-270.37%	4.87%

In the previous week, HealthEquity had 13 more articles in the media than DaVita. MarketBeat recorded 17 mentions for HealthEquity and 4 mentions for DaVita. DaVita's average media sentiment score of 0.81 beat HealthEquity's score of 0.79 indicating that DaVita is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthEquity	4 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DaVita	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.6% of HealthEquity shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 1.6% of HealthEquity shares are held by company insiders. Comparatively, 1.5% of DaVita shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

HealthEquity beats DaVita on 11 of the 16 factors compared between the two stocks.

How does DaVita compare to Merit Medical Systems?

DaVita (NYSE:DVA) and Merit Medical Systems (NASDAQ:MMSI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

In the previous week, Merit Medical Systems had 7 more articles in the media than DaVita. MarketBeat recorded 11 mentions for Merit Medical Systems and 4 mentions for DaVita. DaVita's average media sentiment score of 0.81 beat Merit Medical Systems' score of 0.80 indicating that DaVita is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Merit Medical Systems	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

90.1% of DaVita shares are held by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are held by institutional investors. 1.5% of DaVita shares are held by company insiders. Comparatively, 0.7% of Merit Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

DaVita has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Merit Medical Systems has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

DaVita currently has a consensus price target of $199.17, indicating a potential upside of 4.67%. Merit Medical Systems has a consensus price target of $92.80, indicating a potential upside of 49.56%. Given Merit Medical Systems' stronger consensus rating and higher possible upside, analysts plainly believe Merit Medical Systems is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38
Merit Medical Systems	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

DaVita has higher revenue and earnings than Merit Medical Systems. DaVita is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	0.90	$746.80M	$10.78	17.65
Merit Medical Systems	$1.52B	2.44	$128.49M	$2.31	26.86

Merit Medical Systems has a net margin of 9.03% compared to DaVita's net margin of 5.65%. Merit Medical Systems' return on equity of 13.54% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	5.65%	-270.37%	4.87%
Merit Medical Systems	9.03%	13.54%	7.94%

Summary

Merit Medical Systems beats DaVita on 10 of the 17 factors compared between the two stocks.

How does DaVita compare to Cardinal Health?

DaVita (NYSE:DVA) and Cardinal Health (NYSE:CAH) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

In the previous week, DaVita and DaVita both had 4 articles in the media. Cardinal Health's average media sentiment score of 0.97 beat DaVita's score of 0.81 indicating that Cardinal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardinal Health	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DaVita has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Cardinal Health has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

DaVita presently has a consensus price target of $199.17, indicating a potential upside of 4.67%. Cardinal Health has a consensus price target of $241.80, indicating a potential upside of 23.79%. Given Cardinal Health's stronger consensus rating and higher possible upside, analysts plainly believe Cardinal Health is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38
Cardinal Health	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94

Cardinal Health has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	0.90	$746.80M	$10.78	17.65
Cardinal Health	$222.58B	0.21	$1.56B	$6.54	29.87

90.1% of DaVita shares are held by institutional investors. Comparatively, 87.2% of Cardinal Health shares are held by institutional investors. 1.5% of DaVita shares are held by company insiders. Comparatively, 0.1% of Cardinal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

DaVita has a net margin of 5.65% compared to Cardinal Health's net margin of 0.62%. Cardinal Health's return on equity of -92.61% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	5.65%	-270.37%	4.87%
Cardinal Health	0.62%	-92.61%	4.46%

Summary

Cardinal Health beats DaVita on 8 of the 15 factors compared between the two stocks.

Get DaVita News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DVA vs. The Competition

Export

Metric	DaVita	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$12.22B	$5.48B	$6.31B	$23.24B
Dividend Yield	N/A	1.56%	2.68%	4.09%
P/E Ratio	17.65	33.58	21.13	30.90
Price / Sales	0.90	26.89	546.66	24.79
Price / Cash	8.95	16.23	27.44	19.43
Price / Book	-35.97	3.12	9.95	4.72
Net Income	$746.80M	$218.81M	$3.56B	$1.07B
7 Day Performance	-4.09%	-1.53%	2.12%	1.37%
1 Month Performance	N/A	N/A	N/A	0.45%
1 Year Performance	39.82%	12.22%	36.38%	27.94%

DaVita Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DVA DaVita	4.1971 of 5 stars	$190.28 -2.1%	$199.17 +4.7%	+42.7%	$12.22B	$13.64B	17.65	78,000
ALGN Align Technology	2.984 of 5 stars	$163.61 flat	$205.85 +25.8%	-3.2%	$11.72B	$4.03B	27.45	20,290
DXCM DexCom	4.358 of 5 stars	$72.10 flat	$82.21 +14.0%	-14.2%	$27.82B	$4.66B	30.81	11,000	Positive News
HQY HealthEquity	4.2084 of 5 stars	$88.11 flat	$111.79 +26.9%	-13.0%	$7.39B	$1.31B	35.82	2,814	Earnings Report Analyst Forecast
MMSI Merit Medical Systems	4.6827 of 5 stars	$64.17 flat	$92.80 +44.6%	-33.6%	$3.83B	$1.52B	27.78	7,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DVA) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DaVita (DVA) Competitors

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

How does DaVita compare to Align Technology?

Summary

How does DaVita compare to DexCom?

Summary

How does DaVita compare to HealthEquity?

Summary

How does DaVita compare to Merit Medical Systems?

Summary

How does DaVita compare to Cardinal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DVA vs. The Competition

DaVita Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DaVita (DVA) Competitors

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

How does DaVita compare to Align Technology?

Does the media favor ALGN or DVA?

Which has more risk and volatility, ALGN or DVA?

Which has preferable valuation & earnings, ALGN or DVA?

Do insiders & institutionals have more ownership in ALGN or DVA?

Is ALGN or DVA more profitable?

Do analysts recommend ALGN or DVA?

Summary

How does DaVita compare to DexCom?

Do analysts rate DXCM or DVA?

Is DXCM or DVA more profitable?

Does the media favor DXCM or DVA?

Which has higher earnings and valuation, DXCM or DVA?

Which has more risk & volatility, DXCM or DVA?

Do institutionals and insiders believe in DXCM or DVA?

Summary

How does DaVita compare to HealthEquity?

Which has more risk & volatility, HQY or DVA?

Which has preferable valuation and earnings, HQY or DVA?

Do analysts recommend HQY or DVA?

Is HQY or DVA more profitable?

Does the media favor HQY or DVA?

Do institutionals & insiders hold more shares of HQY or DVA?

Summary

How does DaVita compare to Merit Medical Systems?

Does the media refer more to DVA or MMSI?

Do institutionals and insiders believe in DVA or MMSI?

Which has more risk & volatility, DVA or MMSI?

Do analysts rate DVA or MMSI?

Which has better valuation & earnings, DVA or MMSI?

Is DVA or MMSI more profitable?

Summary

How does DaVita compare to Cardinal Health?

Does the media refer more to DVA or CAH?

Which has more volatility and risk, DVA or CAH?

Do analysts rate DVA or CAH?

Which has preferable valuation and earnings, DVA or CAH?

Do institutionals and insiders have more ownership in DVA or CAH?

Is DVA or CAH more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DVA vs. The Competition

DaVita Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools